Date of Award


Degree Type

Selective Evidence-Based Medicine Review

Degree Name

Master of Science in Health Sciences - Physician Assistant


Physician Assistant Studies

Department Chair

John Cavenagh, MBA, PhD, PA-C


A. Objective: The objective of this selective EBM review is to determine whether or not intravenous Peramivir 300mg is effective and safe in treating seasonal influenza.

B. Study Design: Review of two randomized controlled trials (RCTs) and one randomized open-label study, all published in 2010, 2011, and 2014, respectively.

C. Data sources: Two randomized controlled trials and one randomized open- label study were all researched through the use of PubMed and belonged to peer reviewed journals.

D. Outcome(s) Measured: Primary efficacy endpoint analyzed was time to alleviation of symptoms measured by influenza symptom severity scale (ISS), a self-assessment four point scale. The primary safety endpoint measure was incidence of adverse events. The Fischer’s exact test was used for intergroup comparison of the safety endpoint.

E. Results: When comparing alleviation of symptoms in all three studies, 300mg Peramivir was as effective as 600mg Peramivir. Both Peramivir groups were superior to the efficacy of placebo. Analysis of safety, using adverse events, displayed no significant difference between 300mg Peramivir and comparison groups.

F. Conclusions: After analysis of the three studies in this review, there is significant data to show 300mg Peramivir is effective and safe in treatment of seasonal influenza.